Lilly supera Novo no mercado de GLP-1 oral (LLY:NYSE)
· seekingalpha.com
A terapia oral de GLP-1 da Eli Lilly (LLY), Foundayo, supera as estimativas de vendas do segundo trimestre de 2026, acirrando a rivalidade com a pílula Wegovy da Novo (NVO). Leia mais aqui.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...